- Home
- WSC vs AXSM Comparison
WSC vs AXSM Comparison
Compare WSC & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSC
- AXSM
- Stock Information
- Founded
- WSC 1944
- AXSM 2012
- Country
- WSC United States
- AXSM United States
- Employees
- WSC N/A
- AXSM N/A
- Industry
- WSC Misc Corporate Leasing Services
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- WSC Industrials
- AXSM Health Care
- Exchange
- WSC Nasdaq
- AXSM Nasdaq
- Market Cap
- WSC 4.8B
- AXSM 5.1B
- IPO Year
- WSC N/A
- AXSM 2015
- Fundamental
- Price
- WSC $27.96
- AXSM $104.19
- Analyst Decision
- WSC Buy
- AXSM Strong Buy
- Analyst Count
- WSC 9
- AXSM 16
- Target Price
- WSC $40.63
- AXSM $170.50
- AVG Volume (30 Days)
- WSC 1.8M
- AXSM 655.7K
- Earning Date
- WSC 07-31-2025
- AXSM 08-04-2025
- Dividend Yield
- WSC 0.99%
- AXSM N/A
- EPS Growth
- WSC N/A
- AXSM N/A
- EPS
- WSC 0.08
- AXSM N/A
- Revenue
- WSC $2,368,088,000.00
- AXSM $432,157,000.00
- Revenue This Year
- WSC N/A
- AXSM $62.84
- Revenue Next Year
- WSC $5.14
- AXSM $60.02
- P/E Ratio
- WSC $354.16
- AXSM N/A
- Revenue Growth
- WSC N/A
- AXSM 72.16
- 52 Week Low
- WSC $21.91
- AXSM $72.21
- 52 Week High
- WSC $43.80
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- WSC 55.29
- AXSM 43.11
- Support Level
- WSC $27.11
- AXSM $99.75
- Resistance Level
- WSC $28.10
- AXSM $105.03
- Average True Range (ATR)
- WSC 0.82
- AXSM 3.38
- MACD
- WSC 0.08
- AXSM -0.28
- Stochastic Oscillator
- WSC 71.24
- AXSM 22.86
About WSC WillScot Mobile Mini Holdings Corp.
WillScot Holdings Corp designs, delivers, and services onsite, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company includes modular office complexes, mobile offices, portable storage containers, and others.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.